The Tide Company Buys the $4 Billion Vitamin

Procter & Gamble, the company that makes Tide and Crest, is buying a vitamin pill company. The deal, which is set to be officially announced today, sends PG's stock up about 1.5% to around $147. That's not a dramatic move for a company that has been falling rather than rising for most of the past two months.

The weirder part isn't who P&G is buying. It's what the seller is getting paid, relative to how much the buyer actually needs.

Thorne is a nutritional supplements brand founded in 1984. L Catterton, a consumer-focused private equity firm, bought it in 2023 for $680 million, when Thorne was generating roughly $229 million in revenue. That was a tidy entry. Thorne more than doubled its revenue over the next two years, crossing $500 million in 2025 and heading toward $650 million this year, growing at a compound annual rate above 30 percent. The brand has been popular with younger consumers who, as Thorne's CEO put it, "don't think about supplementation as prevention. They think about it as performance." They want to sleep better, have more energy, deal with anxiety.

Now L Catterton is selling Thorne at a valuation of up to $4 billion.

$680 million to $4 billion in roughly three years. That's a 5.9x multiple on the entry price, or about a 78 percent annualized return if you ignore the messy details of how revenue was grown and costs were financed. It's the sort of outcome that makes private equity newsletters very pleased with themselves.

P&G won the deal. It wasn't the only interested buyer. In late June, reports emerged that Haleon, the consumer health spin-off of GSK and Pfizer that makes Tums and Advil, was near a deal for Thorne. Unilever was also exploring a bid. The Financial Times reported that several buyers were in the running.

The race for Thorne is the more interesting story than the deal itself. Because all three of these companies - P&G, Haleon, Unilever - are consumer goods companies that have run out of easy growth and are now hunting for something to buy.

P&G reported its fiscal year-end results last week. Organic sales growth was 1 percent for the full year, and Q4 organic volumes were flat. The core operating margin fell for the third straight quarter. P&G expects 1 percent to 3 percent net sales growth in fiscal 2027, down from 3.3 percent in fiscal 2026. The CEO called it "foundation building" while navigating a "very challenging geopolitical and economic environment." That's P&G-speak for: we are a $87 billion company that can't figure out how to grow much anymore.

The Thorne deal adds roughly $650 million in annual revenue to P&G's $87 billion base. That's about 0.75 percent. If Thorne really is the billion-dollar brand its management expects, it might add another 1.2 percent to P&G's top line. Not transformative. But P&G's own organic growth is already down in the single digits, so anything that grows in the teens or twenties looks good by comparison.

Here's the mechanism, stripped down. You have a company that makes detergent, toothpaste, and diapers. The categories are mature. Volume growth is flat or negative in most segments. The margin is getting squeezed by higher commodity costs - P&G expects roughly $1 billion in headwinds from raw material, energy, and transportation costs in fiscal 2027, partly a fallout from the U.S. war in Iran. At the same time, a private equity firm sits on a small supplement brand it has turned into a high-growth story and is running a competitive auction to exit.

P&G's CEO Shailesh Jejurikar told CNBC that the price is "a good price for the growth rates they have" and "kind of in line with the industry benchmarks we've seen." This is a very polite way of saying: we're paying a rich multiple for a revenue stream that's small relative to our business but growing fast enough to distract from the fact that the rest of our business barely is.

It's not even the first wellness buy this year. P&G acquired Wonderbelly, a digestive health brand, in January. That one joined an existing portfolio that includes Metamucil, Pepto-Bismol, and Prilosec OTC. This time, supplements are the target. The wellness push is becoming a strategy, or at least a procurement pattern.

The question isn't whether P&G should buy a growing supplements brand. The question is whether the 6x revenue multiple - $4 billion for a company doing $650 million this year, perhaps $1 billion a few years out - is something P&G can afford, given its own margin pressure and growth slowdown. A $4 billion acquisition is material for a company whose own earnings growth is in the low single digits. The deal has to earn its keep, not just as a revenue addition but as something that justifies diverting capital away from the core business that already needs investment.

L Catterton has no such problem. Their return is already locked in at the valuation level. The buyer is the one doing the math.

This is the standard private equity flip, dressed in consumer goods clothing. Buy a brand, grow the revenue, run an auction among desperate legacy operators, and take the check. The fact that there were multiple bidders - Haleon, Unilever, and now P&G - means the auction worked exactly as designed. The competition ensured the price moved up, not down.

The stock reaction today is mild. Up 1.5 percent, which is barely enough to close the gap from where PG was a week ago. The market isn't selling the deal as a transformative growth move. It's probably reading it for what it is: a consumer goods company buying a small fast-growing brand at a high multiple because it has limited organic options and needed to show it could still expand.

P&G has a cash flow machine. It generated $19.6 billion in operating cash flow last fiscal year and returned over $15 billion to shareholders. It can afford to write a $4 billion check without breaking anything. The structural question is whether this is the sort of investment that compounds or the sort that gets absorbed. At 1 percent of current revenue, Thorne is a signal of intent more than a change in trajectory. The signal itself - that P&G is serious about wellness and willing to pay for growth - is what the stock is voting on today.